VANCOUVER, BC / ACCESSWIRE / December 16, 2020 / Pacific Frontier Investments Inc. ("PFI") is pleased to announce it has taken possession of an RV park and campground located in Parksville, B.C. on Vancouver Island. This acquisition represents the 3rd location added to Canada's newest brand of RV and Campgrounds, known as Pathfinder Camp Resorts.

The latest Pathfinder Camp Resort location is a 12+ acre property located on the Englishman River with low bank access to several swimming holes and a sandy beach area. The property is quiet and peaceful yet it's only minutes from all shopping in downtown Parksville.

The site currently has 77 full hookup sites, 21 water and electric sites and 62 un-serviced tenting sites. The property offers guests a heated outdoor swimming pool, convenience/gift store, washrooms with hot showers, laundry, playground and horseshoe pits.

The Company plans to upgrade and improve the current infrastructure prior to opening for the 2021 season. Improvements include upgrading the electrical on each RV site to 30/50-amp power, as well as increasing the water and septic service.

The Company anticipates reservations will open mid-January where campers can start booking for spring and summer stays.

Expansion and Acquisition Pipeline

PFI is committed to the growth of its Pathfinder Camp Resorts brand and has several acquisitions in its pipeline that meet the brand's criteria.

Recently Announced Private Placement Increased

On Dec 7, 2020 PFI announced an increase to its previously announced non-brokered private placement from $2,100,000 to $4,900,000. The terms of the non-brokered private placement remain unchanged whereby the Company is offering a Common Share at a price of $0.07 per share for gross proceeds of up to $4,900,000.

Qualifying Transaction with Discovery One Investments Corp. (TSXV: DOIT.P) "DOIT"

PFI's plans to list on the TSX Venture Exchange remain on track where the arrangement will represent a Reverse-Take-Over transaction of DOIT by PFI. The amalgamation is expected to close on or about Feb. 28, 2021. Trading in DOIT's shares will remain halted until completion of the amalgamation. Complete details regarding PFI, the amalgamation and the financing will be contained in a filing statement which will be filed on SEDAR prior to closing.

For further information, please contact:

Pacific Frontier Investments Inc.
Joe Bleackley- Chief Executive Officer, Founder and Director
Phone: (604) 914-2575
Email: ir@pacificfrontier.co

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward-Looking Information Cautionary Statement

This news release contains forward-looking statements relating to the timing and completion of the Transaction, the future operations of the Corporation and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Transaction and the future plans and objectives of the Corporation, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Corporation's expectations include the failure to satisfy the conditions to completion of the Transaction set forth above and other risks detailed from time to time in the filings made by the Corporation with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Corporation. As a result, the Corporation cannot guarantee that the Transaction will be completed on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Corporation will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

In the case of PFI, this news release includes certain "forward-looking statements" which are particular to PFI and are not comprised of historical facts. Forward-looking statements include estimates and statements that describe PFI's future plans, objectives or goals, including words to the effect that PFI or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to PFI, PFI provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, PFI's objectives, goals or future plans, statements, its projected revenues and earnings, and anticipated future growth in new markets. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, the ability of the PFI to successfully implement its development strategy and whether this will yield the expected benefits; competitive factors in PFI's industry sector; the success or failure of product development programs; currently existing applicable laws and regulations or future applicable laws and regulations that may affect PFI' s business; decisions of regulatory authorities and the timing thereof; Covid-19 related risks, availability of properties; the economic circumstances surrounding PFI's business, including general economic conditions in Canada, the US and worldwide; changes in exchange rates; changes in the equity market; inflation; uncertainties relating to the availability and costs of financing needed in the future; and those other risks to be disclosed in the filing statement or other disclosure document to be prepared in connection with the Transaction. Although PFI believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. PFI disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

SOURCE: Pacific Frontier Investments Inc.

ReleaseID: 621106

VANCOUVER, WA / ACCESSWIRE / December 16, 2020 / Adaptive Ad Systems, Inc. (OTC PINK:AATV), today announces that its campaign advertisement sales for the month of December continue unabated. Adaptive previously projected election campaign ad revenue to continue into the month of December and early January, on the heels of two months of record revenue for October and November 2020, after already reporting the largest revenue for any months of August and September in the Company's history before.

Adaptive and its subsidiary companies provide Dynamic Digital Ad Insertion (DDAI) via its streaming media hardware and proprietary processing software for all U.S. cable TV markets, and High Speed Fixed Wireless Internet Service (WISP) via a network of Hybrid Access Points and Micro POPs.

Though the U.S. House of Representatives remains in control of the Democratic Party by a slim margin, control of the U.S. Senate is yet to be determined. While all states, except for Georgia, have finalized their election results, Georgia is the only state with a special (run-off) election on January 5, 2021 to determine two remaining U.S. Senate seats, not just one. The results of those two races in Georgia will determine which political party will have control of the United States Senate.

Adaptive's CEO, J. Michael Heil, states: "Two days ago, America's electoral college completed its constitutional task. Now, all eyes are on Georgia. The results of Georgia's special election will not only affect politics of Georgia and government of the United States, but its impact will extend to the entire world, affecting America's foreign policy for years to come. Consequently, both parties are holding highly publicized campaign events and are continuing to make aggressive media-time investments to promote their respective candidates."

As previously reported, Adaptive's national cable advertising network includes multiple systems in Georgia. Adaptive sells and inserts advertising for over 15 cable systems in Georgia covering multiple Demographic Market Areas, including Atlanta, Columbus, Albany, and Macon, with systems also covering smaller communities.

Mr. Heil continues: "Because the presidential election in Georgia was determined by approximately 12,000 votes with variances in "down-ballot" results, every vote in every town and city in Georgia will be important in determining control of the United States Senate with this state-wide special election. Accordingly, the candidates and their respective political parties are still investing heavily in traditional television advertising. Our sales and technology teams will be working through the holidays to accommodate both parties and complete all digital ad insertions throughout the entire month of December."

THE ADAPTIVE SYSTEM:

Adaptive Ad Systems Inc. is a digital media and video communications company. Together with its subsidiaries and manufactures it develops and deploys Dynamic Digital Ad Insertion (DDAI) streaming media hardware and proprietary processing software for the Cable TV, Satellite, and IPTV markets. Via its subsidiary Adaptive Broadband, it provides High-Speed Fixed Wireless Internet Service (WISP) to residences and small businesses. The Company's DDAI and WISP services target the often-over-looked 2nd and 3rd Tier cable TV and rural WIFI markets, and now also Tier 1 markets. Adaptive's proprietary software and hardware, installed in scores of cable television systems across the United States, creates a "network" of linked cable systems. This allows advertisers to purchase ads across the entire National Adaptive network, generating significantly more ad impressions than through the traditional ad insertion technologies in individual systems. Adaptive Ad Systems has established an innovative revenue sharing agreement with each individual system and manages all ad-related activities. Currently, the Company serves over 75 designated marketing areas in over 40 states. The Adaptive Broadband network system provides services via a network of Hybrid Access Points and Micro POPs. For additional information, please visit: www.aatv.co.

FORWARD-LOOKING STATEMENTS:

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for current and future operations, the development, regulatory approvals, and commercialization of the Company's products, or any of the Company's proposed services, systems, services, licensing arrangements, joint ventures, partnerships, or acquisitions. Such forward-looking statements are not meant to predict or guarantee actual results and performance and actual events or results may differ considerably. Factors that may cause actual results to differ materially from any projections may include, without limitation, delays in the Company's development of its products and services, the inability to obtain additional financing, the impact of significant new or changing government regulation on the industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's general failure to effectively implement the Company's business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any change in events or circumstances that may arise after the date of this release.

CONTACT:

Adaptive Ad Systems, Inc.
4400 NE 77th Avenue Suite 275
Vancouver, Washington 98662
310-321-4958
info@aatv.co
www.aatv.co

StockWatchIndex
San Diego, California
442-287-8059
info@stockwatchindex.com
www.stockwatchindex.com
www.swiresearch.com

SOURCE: Adaptive Ad Systems, Inc.

ReleaseID: 621109

VANCOUVER, BC / ACCESSWIRE / December 16, 2020 / HAWKEYE Gold & Diamond Inc. (the "Company" or "HAWKEYE") (TSX.V-HAWK; Frankfurt Ticker:HGT; ISIN:CA42016R3027; WKN:A12A61): is pleased to announce that HAWKEYE has received approval from the BC Ministry of Energy, Mines and Petroleum Resources for its Multi-Year Area-Based Permit which authorizes the Company to perform work programs over the Boomerang property which includes but is not limited to ground-based geophysical surveys and drilling.

About HAWKEYE

HAWKEYE Gold & Diamond Inc. is a junior mineral exploration and development company based in Vancouver, British Columbia, Canada. The Company's precious and base metals properties are located in the prolific Golden Triangle of northwest BC, in the world-class Barkerville gold camp, and on Vancouver Island, BC, Canada. HAWKEYE's corporate mandate is to build strong asset growth and shareholder value through the acquisition of low-cost, high-potential opportunities with discovery potential, and to manage its business in an environmentally responsible manner while contributing to the local community and economy.

HAWKEYE GOLD & DIAMOND INC.
Per:

"Greg Neeld"

President & CEO
Vancouver: (778) 379-5393
Email: greg@hawkeyegold.com
Web Site: www.hawkeyegold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notes Regarding Forward Looking Statements

This News Release contains forward-looking statements. Forward-looking statements are statements that relate to future events. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our industry, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

SOURCE: HAWKEYE Gold & Diamond Inc.

ReleaseID: 621124

VICTORIA, BC / ACCESSWIRE / December 16, 2020 / Erin Ventures Inc. ("Erin" or the "Company") (TSXV:EV) is pleased to announce that it has completed its non-brokered private placement offering initially announced yesterday, December 15, 2020, for an aggregate amount of gross proceeds of $605,000.00.

Pursuant to the terms of the private placement, Erin issued 12,100,000 units ("Units") at a price of $0.05 per Unit. Each Unit consists of one (1) common share in the capital of the Company and one (1) common share purchase warrant (a "Warrant"). Each Warrant will has a two (2) year term (the "Exercise Period") and will be exercisable into one (1) common share at a price of $0.075.

The Warrants also have an acceleration clause whereby if the Common Shares trade on the TSXV at a price equal or greater than the designated trigger price of $0.10 for more than ten (10) consecutive trading days during the Exercise Period, Erin shall have the right to give written notice to the holder requiring the holder to exercise the Warrant, in whole or in part, within a period of thirty (30) days from the date of receipt of notice from Erin.

The net proceeds from this financing will be used to fund further development of its wholly owned Piskanja boron project in Serbia, and for working capital purposes.

The offering was conducted on a private placement basis pursuant to prospectus exemptions of applicable securities laws and remains subject to final acceptance by the TSXV. The Common Shares and Warrants comprising the Units will be subject to a four (4)-month and one day hold period in accordance with the policies of the TSXV and applicable securities laws. Three (3) arm's length finders are to be paid an aggregate amount of finders' fees equal to $11,500 in accordance with the rules of the TSXV Corporate Finance Manual.

On behalf of the Board of Directors,
Blake Fallis, General Manager

About Erin Ventures

Erin Ventures Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Erin's shares are traded on the TSX Venture Exchange under the symbol "EV" and the OTCQB Venture Market under the symbol "ERVFF". For detailed information please see Erin's website at www.erinventures.com or the Company's filed documents at www.sedar.com.

For further information, please contact:

Erin Ventures Inc.
Blake Fallis, General Manager
Phone: 1-250- 384-1999 or 1-888-289-3746
info@erinventures.com
www.erinventures.com

Erin's Public Quotations:

Canada
TSX Venture:EV
USA
OTCQB:ERVFF
Europe
Berlin:EKV

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

This release contains forward looking statements. The words "believe," "expect," "feel," "plan," "anticipate," "project," "could," "should" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties including, without limitation, variations in estimated costs, the failure to discover or recover economic grades of minerals, and the inability to raise the funds necessary, changes in external market factors including commodity prices, and other risks and uncertainties. Actual results could differ materially from the results referred to in the forward-looking statements.

SOURCE: Erin Ventures Inc.

ReleaseID: 621256

LONDON, UK / ACCESSWIRE / December 16, 2020 / Orosur Mining Inc. ("Orosur" or "the Company") (TSX:OMI) (AIM:OMI) announces that at the Company's Annual General Meeting ("AGM") held at 2:00 p.m. GMT today, all resolutions put to shareholders were duly passed.

AGM Voting Results

At the AGM, a total of 43,851,102 common shares of the 163,529,341 shares outstanding as at the November 6, 2020 record date, were voted at the meeting, representing approximately 26.8% of the issued and outstanding common shares of the Company. The nominees listed in the Company's management proxy circular were re-elected as directors as follows:

Nominee

Votes for

% Votes for

Votes
withheld

% Votes withheld

Louis Castro

43,361,185

99.99%

3,500

0.01%

Brad George

39,620,435

91.37%

3,744,250

8.63%

Thomas Masney

43,361,184

99.99%

3,501

0.01%

For further information, please contact:

Orosur Mining Inc
Louis Castro, Chairman,
Brad George, CEO
info@orosur.ca
Tel: +1 (778) 373-0100

Turner Pope Investments (TPI) Ltd – Joint Broker
Andy Thacker
Tel: +44 (0)20 3657 0050

SP Angel Corporate Finance LLP – Nomad & Broker
Jeff Keating / Caroline Rowe
Tel: +44 (0) 20 3 470 0470

Flagstaff Communications
Tim Thompson
Mark Edwards
Fergus Mellon
orosur@flagstaffcomms.com
Tel: +44 (0)207 129 1474

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR"). Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

About Orosur Mining Inc.

Orosur Mining Inc. (TSX:OMI; AIM:OMI) is a precious metals developer and explorer focused on identifying and advancing gold projects in South America. The Company operates in Colombia and Uruguay.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Orosur Mining Inc.

ReleaseID: 621183

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2020 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.

OVERVIEW

The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (2019 – $2,214,000). Net loss and comprehensive loss for the three-month period ending October 31, 2020 included a gain from loss of control in Helix Immuno-Oncology S.A. ("HIO") of $2,162,000 (2019 – $nil) on September 3, 2020.

On November 9, 2020, the Company announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ("CAIAC") to purchase the Company's remaining 29.89% holdings in Helix Immuno-Oncology S.A. ("HIO"), for gross proceeds of PLN 6,700,000 ($2,308,000). Closing of the transaction is to occur upon finalizing administrative reporting requirements and evidence of share registry changes in Poland. The Company expects to close the transaction in the very near term. A finder's fee is owed to ACM Establishment Management Est ("ACMest") upon closing of the transaction equal to 12.5% of the gross proceeds.

At present, the only clinical program enrolling patients is the Company's U.S. Phase Ib/II LDOS006 study (L-DOS47 in combination with doxorubicin) in the treatment of patients with metastatic pancreatic cancer who have progresses on at least two prior treatment regimens. One patient has experienced a chemo-related dose limiting toxicity and thus, three additional patients will need to be enrolled to close cohort 1. Due to slower enrolment related to challenges resulting from COVID-19 pandemic measures, an additional two sites are engaged in study start-up activities, with plans to be open for patient recruitment in the first calendar quarter of fiscal 2021. A protocol amendment is also planned for submission to the U.S. Food and Drug Administration by the end of the month.

The Company is working through the process of completing the anti-drug antibody assays for LDOS001 (U.S. Phase I L-DOS47 in combination with pemetrexed and carboplatin for lung cancer) with the goal of finalizing the clinical study report by April 2021 while for LDOS003 (European Phase II L-DOS47 in combination with vinorelbine and cisplatin for lung cancer) the Company has experienced delays in completing final monitoring, close out activities and finalizing the clinical study report LDOS003.

On December 4, 2020, the Company closed a private placement financing of 2,200,000 units at a price of $0.50 per unit, for aggregate gross proceeds of $1,100,000. Each unit consisted of one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share of the Company at a price of $0.70 and have an expiry of five years from the date of issuance. A finder's fee is owed to ACM Establishment Management AG ("ACMag") upon closing of the transaction equal to 12.5% of the gross proceeds

Both ACMag and ACMest were involved in the sourcing of these transactions prior to both parties' mutual agreement to terminate the respective contractual agreements. The ACMag agreement incorporates a tail provision whereby in the event ACMag sources financing and the Company closes a transaction within six months of terminating the agreement, a fee of 12.5% of gross proceeds would be due to ACMag.

The Company continues to work towards a qualifying Nasdaq listing.

Research and development

Research and development expense for the three-month periods ended October 31, 2020 and 2019 totalled $1,084,000 and $1,446,000, respectively.

Components of research and development expenses for the three-month periods ended October 31:

 
2020
 
 
2019
 

Operating, general and administration, excluding the below items

 
$
776,000
 
 
$
423,000
 

Salaries and benefits

 
$
107,000
 
 
$
120,000
 

Stock-based compensation expense

 
$
420,000
 
 
$
33,000
 

Amortization of property, plant and equipment

 
 
–
 
 
 
–
 

Amortization of right of use assets

 
 
–
 
 
 
–
 

 
$
1,303,000
 
 
$
576,000
 

The decrease in research and development expenses for the current quarter, when compared to the prior year's quarter is the result of lower clinical operation expense of $140,000, lower intellectual property maintenance cost of $139,000, lower collaborative scientific research expenditures of $80,000 and lower manufacturing costs of $20,000.

Lower clinical operation expenses are due to spending having occurred in the prior year's quarter related to the Company's LDOS003 Phase II clinical study in Poland and the Ukraine which has since concluded but currently awaiting reporting. The Company's new LDOS006 Phase Ib/II pancreatic clinical study in the U.S. was still in the early stages with U.S. FDA approval only having been received in August 2019.

Lower intellectual property maintenance costs are mainly the result of the Company having occurred higher costs over the previous years and timing related spend which is forecasted for the second fiscal quarter ending January 31, 2021.

Lower collaborative scientific research spend mainly reflects the conclusion of a previous research project with the Moffit Cancer Center. A new collaboration has since been agreed upon with work having commenced in November.

Operating, general and administration

Operating, general and administration expenses for the three-month periods ended October 31, 2020 and 2019 totalled $1,303,000 and $576,000, respectively.

Components of operating, general and administration expenses for the three-month periods ended October 31:

 
2020
 
 
2019
 

Research and development programs, excluding the below items

 
$ 
689,000
 
 
$ 
1,106,000
 

Salaries and benefits

 
$ 
315,000
 
 
$ 
257,000
 

Stock-based compensation expense

 
$ 
4,000
 
 
$ 
39,000
 

Amortization of property, plant and equipment

 
$ 
17,000
 
 
$ 
12,000
 

Amortization of right of use assets

 
$ 
32,000
 
 
$ 
32,000
 

Research and development investment tax credits

 
$ 
27,000
 
 
 
–
 

 
$ 
1,084,000
 
 
$ 
1,446,000
 

The increase in operating, general and administration expense for the current quarter, when compared to the prior year's quarter is the result of higher legal costs of $148,000, higher audit fees of $65,000 and higher investor relations expenditures of $153,000.

The Company has been in discussions with various groups both in the U.S. and Canada and has been incurring additional legal and audit expenses as part of the Company's objective to raise additional capital in order to qualify for a listing on a U.S. stock exchange such as NASDAQ. On October 21, 2020 the agreement with ACM Alpha Consulting Management EST ("AGMest") was terminated by mutual agreement of the parties. The agreement included a termination clause which required a ninety-day written notice resulting in a payout of $144,000.

Stock based compensation expense for the three-month period ended October 31, 2020 totalled $420,000 (2019 – $33,000). The amount represents the expense associated with the vesting of stock options that were granted to directors of the Company, over their vesting period.

LIQUIDITY AND CAPITAL RESOURCES

The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (October 31, 2019 – $2,214,000). As at October 31, 2020 the Company had working capital of $2,426,000, shareholders' equity of $2,596,000 and a deficit of $180,738,000. As at July 31, 2020 the Company had working capital of $2,735,000, shareholders' equity of $2,981,000, a deficit of $180,516,000.

On November 9, 2020, the Company announced that it has signed a definitive share purchase agreement with CAIAC to purchase the Company's remaining holdings in its Polish subsidiary, HIO, for gross proceeds of PLN6,700,000 (CAD2,308,000).

Irrespective of the private placement closed on November 4, 2020 and the expected close of the CAIAC transaction in the near term, the Company's cash reserves are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see planned research and development initiatives through to completion. Additional funds are required to advance the Company's clinical and preclinical programs and deal with working capital requirements. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be critical for its development needs.

The Company's Statement of Financial Position and Statement of Net Loss and Comprehensive Loss for the fiscal periods October 31, 2020 and 2019 are summarized below:

Condensed unaudited Statement of Financial Position

 
 
Q1F2021
 
 
FY2020
 

Current assets:

Cash

 
 
1,428,000
 
 
 
4,235,000
 

Accounts receivable

 
 
166,000
 
 
 
180,000
 

Prepaids

 
 
168,000
 
 
 
90,000
 

Investment in Associate held for sale

 
 
2,646,000
 
 
 
–
 

Assets held for sale

 
 
–
 
 
 
155,000
 

 
 
4,408,000
 
 
 
4,660,000
 

Non current assets

PPE's

 
 
73,000
 
 
 
91,000
 

Right of use assets

 
 
97,000
 
 
 
155,000
 

 
 
170,000
 
 
 
246,000
 

Total assets

 
 
4,578,000
 
 
 
4,906,000
 

Current liabilities:

Accounts payable

 
 
1,685,000
 
 
 
1,416,000
 

Accrued liabilities

 
 
198,000
 
 
 
301,000
 

Lease liabilities

 
 
99,000
 
 
 
159,000
 

Liabilities held for sale assets

 
 
–
 
 
 
49,000
 

 
 
1,982,000
 
 
 
1,925,000
 

Shareholders' equity

Attributable to Helix

 
 
2,596,000
 
 
 
2,394,000
 

Non-controlling interest

 
 
–
 
 
 
587,000
 

 
 
2,596,000
 
 
 
2,981,000
 

Total liabilities & Shareholders' equity / (deficiency)

 
 
4,578,000
 
 
 
4,906,000
 

Condensed unaudited Statements of Net Loss and Comprehensive Loss

 
 
Q1F2021
 
 
 
Q1F2020
 

Expenses:

Research and development

 
 
1,084,000
 
 
 
1,446,000
 

Operating, general & administration

 
 
1,303,000
 
 
 
576,000
 

Results from operating activities

before finance items

 
 
(2,387,000
)
 
 
(2,022,000
)

Finance items

 
 
3,000
 
 
 
(4,000
)

Net loss from continuing operations

 
 
(2,384,000
)
 
 
(2,026,000
)

Net gain (loss) from discontinued operations

 
 
2,162,000
 
 
 
(188,000
)

Net loss & total comprehensive loss

 
 
(222,000
)
 
 
(2,214,000
)

Equity loss of investment in associate

from discontinued operations

 
 
–
 
 
 
36,000
 

 
 
(222,000
)
 
 
(2,178,000
)

Loss per share continuing operations

 
$
(0.02
)
 
$
(0.02
)

Loss per share discontinued operations

 
$
0.02
 
 
 
–
 

Loss per share – total

 
 
–
 
 
$
(0.02
)

The Company's financial statements, management's discussion and analysis and annual information form will be filed under the Company's profile on SEDAR at www.sedar.com, as well as on the Company's website at www.helixbiopharma.com.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the Toronto Stock Exchange under the symbol "HBP".

Investor Relations

Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300
ir@helixbiopharma.com

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (917) 385-2160
helix@alphabronze.net

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and other information in future periods.

Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for DOS47, L-DOS47, V-DOS47 and CAR-T; (iv) future expenditures, the insufficiency of the Company's current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support.

The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company's annual management's discussion and analysis for the year ended July 31, 2020 under the heading "Risks and Uncertainty" and Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

SOURCE: Helix BioPharma Corp.

ReleaseID: 621105

VICTORIA, BC / ACCESSWIRE / December 15, 2020 / Erin Ventures Inc. ("Erin" or the "Company") (TSXV:EV) announces that, subject to the approval of the TSX Venture Exchange (the "TSXV"), it intends to complete a now fully subscribed private placement offering of 12,100,000 units of the Company ("Units") at a price of $0.05 per Unit for gross proceeds of $605,000.00 (the "Offering").

Each Unit in this Offering will be comprised of one (1) common share in the capital of the Company (a "Share") and one (1) common share purchase warrant (each, a "Warrant"). Each Warrant will have a two (2) year term and will be exercisable into one (1) Share at a price of $0.075.

The Warrants also have an acceleration clause whereby if the Common Shares trade on the TSXV at a price equal or greater than the designated trigger price of $0.10 for more than ten (10) consecutive trading days during the Exercise Period, Erin shall have the right to give written notice to the holder requiring the holder to exercise the Warrant, in whole or in part, within a period of thirty (30) days from the date of receipt of notice from Erin.

The Common Shares and Warrants comprising the Units will be subject to a four-month and one day hold period in accordance with the policies of the TSXV and applicable securities legislation. The Private Placement remains subject to the approval of the TSXV.

The net proceeds from this financing will be used to fund further development of its wholly owned Piskanja boron project in Serbia, and for working capital purposes.

On behalf of the Board of Directors,

Blake Fallis, General Manager

About Erin Ventures
Erin Ventures Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Erin's shares are traded on the TSX Venture Exchange under the symbol "EV" and the OTCQB Venture Market under the symbol "ERVFF". For detailed information please see Erin's website at www.erinventures.com or the Company's filed documents at www.sedar.com.

For further information, please contact: Erin's Public Quotations
Erin Ventures Inc. Canada USA
Blake Fallis, General Manager TSX Venture: EV OTCQB: ERVFF
Phone: 1-250- 384-1999 or 1-888-289-3746
info@erinventures.com Europe
www.erinventures.com Berlin: EKV

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:
This release contains forward looking statements. The words "believe," "expect," "feel," "plan," "anticipate," "project," "could," "should" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties including, without limitation, variations in estimated costs, the failure to discover or recover economic grades of minerals, and the inability to raise the funds necessary, changes in external market factors including commodity prices, and other risks and uncertainties. Actual results could differ materially from the results referred to in the forward-looking statements.

SOURCE: Erin Ventures Inc.

ReleaseID: 621077

NICOSIA, CYPRUS / ACCESSWIRE / December 15, 2020 / Atalaya Mining Plc ("Atalaya" or "the Company") (AIM:ATYM)(TSX:AYM) announces that further to the TR-1 announcements of 26 November 2020 and 15 December 2020, and in accordance with the terms of the Subscription Agreement between Orion Mine Finance (Master) Fund 1, L.P. and the Company, Mr. Jonathan Lamb has stepped down as a Non-Executive Director of Atalaya, with immediate effect.

Mr. Lamb was appointed as a Non-Executive Director in September 2015. Mr. Lamb's industry experience and skills set have contributed as shareholder and director of Atalaya to the accomplishments of the Company.

Roger Davey, Chairman of Atalaya Mining plc., commented:

"Mr. Lamb has been both a board member and a shareholder of Atalaya and his experience has made a positive contribution to the growth of the Company. We would like to thank him for his commitment and support and wish him all the best for the future."

Alberto Lavandeira, CEO, commented:

"We should like to thank Jon Lamb for his considerable contribution and support to Atalaya and wish him well in the future."

Contacts:

Newgate Communications

Elisabeth Cowell / Adam Lloyd / Tom Carnegie

+ 44 20 37576880

4C Communications

Carina Corbett

+44 20 3170 7973

Canaccord Genuity

(NOMAD and Joint Broker)

Henry Fitzgerald-O'Connor / James Asensio

+44 20 7523 8000

BMO Capital Markets

(Joint Broker)

Tom Rider / Michael Rechsteiner / Neil Elliot

+44 20 7236 1010

Peel Hunt LLP

(Joint Broker)

Ross Allister / David McKeown

+44 20 7418 8900

About Atalaya Mining Plc

Atalaya is an AIM and TSX-listed mining and development group which produces copper concentrates and silver by-product at its wholly owned Proyecto Riotinto site in southwest Spain. In addition, the Group has a phased, earn-in agreement for up to 80% ownership of Proyecto Touro, a brownfield copper project in the northwest of Spain. For further information, visit www.atalayamining.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Atalaya Mining PLC

ReleaseID: 620991

NICOSIA, CYPRUS / ACCESSWIRE / December 15, 2020 / Atalaya Mining Plc ("Atalaya" or "the Company") (AIM:ATYM)(TSX:AYM) announces that further to the TR-1 announcements of 26 November 2020 and 15 December 2020, and in accordance with the terms of the Subscription Agreement between Orion Mine Finance (Master) Fund 1, L.P. and the Company, Mr. Jonathan Lamb has stepped down as a Non-Executive Director of Atalaya, with immediate effect.

Mr. Lamb was appointed as a Non-Executive Director in September 2015. Mr. Lamb's industry experience and skills set have contributed as shareholder and director of Atalaya to the accomplishments of the Company.

Roger Davey, Chairman of Atalaya Mining plc., commented:

"Mr. Lamb has been both a board member and a shareholder of Atalaya and his experience has made a positive contribution to the growth of the Company. We would like to thank him for his commitment and support and wish him all the best for the future."

Alberto Lavandeira, CEO, commented:

"We should like to thank Jon Lamb for his considerable contribution and support to Atalaya and wish him well in the future."

Contacts:

Newgate Communications

Elisabeth Cowell / Adam Lloyd / Tom Carnegie

+ 44 20 37576880

4C Communications

Carina Corbett

+44 20 3170 7973

Canaccord Genuity

(NOMAD and Joint Broker)

Henry Fitzgerald-O'Connor / James Asensio

+44 20 7523 8000

BMO Capital Markets

(Joint Broker)

Tom Rider / Michael Rechsteiner / Neil Elliot

+44 20 7236 1010

Peel Hunt LLP

(Joint Broker)

Ross Allister / David McKeown

+44 20 7418 8900

About Atalaya Mining Plc

Atalaya is an AIM and TSX-listed mining and development group which produces copper concentrates and silver by-product at its wholly owned Proyecto Riotinto site in southwest Spain. In addition, the Group has a phased, earn-in agreement for up to 80% ownership of Proyecto Touro, a brownfield copper project in the northwest of Spain. For further information, visit www.atalayamining.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Atalaya Mining PLC

ReleaseID: 620991

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESSWIRE / December 14, 2020 / Tracesafe Inc., ("TraceSafe") (CSE:TSF) a global leader in wearable safety tech, including contact tracing and quarantine management, is pleased to announce it will be the exclusive and official contact tracing partner of the 2021 IIHF World Junior Championship in Edmonton, Alberta from December 13, 2020 to January 5, 2021. Powered by the TELUS Communications (T / TU) world-leading wireless network, TraceSafe will provide staff members and players with TraceSafe wearable safety tech solutions across the tournament bubble.

Hockey Canada has developed strict protocols to keep close to 1,000 players, team staff, members of the media, officials, and support personnel safe throughout the 2021 IIHF World Junior Championship. TraceSafe has been selected to provide its comprehensive contact tracing solutions to ensure compliance with health and safety protocols throughout the tournament.

To promote the safety of all participants and the community at large, every tournament member will be required to self-isolate upon arrival in their individual hotel room and will be supplied with a TraceSafe wristband that will enable event organizers to ensure that they self-isolate for the required time.

Additionally, throughout the event, all teams and tournament staff will have TraceSafe's contact tracing beacon embedded in their event credentials. TraceSafe's low powered BLE technology will prompt physical distancing reminders and provide real-time contact tracing for all participants. TraceSafe wearable safety tech will be complemented by regular COVID-19 testing throughout the event.

Data collected by our wearables within the bubble and during the championship is pseudonymized and secured using top-level encryption. Our technology only monitors interactions with other people within authorized locations. Localized contact tracing cannot function once the participant leaves the contact site, eliminating fears of being "always-on". No smartphone app download required.

The 2021 IIHF World Junior Championship will be held using a single-venue format in Edmonton without spectators. The host venue was one of two restart arenas used for the 2020 NHL Stanley Cup Playoffs and has experience in bubble crowd management during COVID-19. TraceSafe has expertise in sports and venue management and this partnership will further solidify TraceSafe as a leading option for venues and sports teams looking to resume action safely.

Executive Quotes

"We are proud to be working with TELUS and Hockey Canada to bring TraceSafe's suite of technology in professional sports and venue management to the World Junior Hockey Championship to ensure all teams, players and staff are safe and secure," said TraceSafe CEO Wayne Lloyd. "This opportunity to support the next generation of athletes with our technology speaks to the growing reputation and trust of the TraceSafe suite of products throughout the international sports community."

"As we continue to prepare for the 2021 IIHF World Junior Championship, we are excited to work with TraceSafe to ensure the health and safety of all participants and the community at large in Edmonton," said Dean McIntosh, vice-president of events and properties with Hockey Canada. "We are grateful to TraceSafe and TELUS for their commitment to participant health and safety, and we know this leading technology will help Hockey Canada and the local organizing committee host a safe, successful event."

"Ensuring the safety and connectivity of the players, staff and other participants at this year's World Junior Hockey Championship is of paramount importance to TELUS," said Andrew Turner, Vice President of Strategic Operations at TELUS. "We are pleased to partner with TraceSafe and Hockey Canada, leveraging our world-leading networks and IoT capabilities to enable comprehensive and secure protection and connectedness throughout the tournament, ensuring Canadians have the opportunity to cheer on our reigning champions as they once again go for gold."

About TraceSafe powered by TELUS

What does it mean to be powered by the best? During the World Juniors, TraceSafe's quarantine management and contact tracing solutions will be powered by TELUS. Their powerful network will ensure uninterrupted connectivity for all TraceSafe wearables and gateways. All wearable devices will be branded with "TraceSafe powered by TELUS".

About TraceSafe

TraceSafe is a full suite of real-time location management services and contact tracing solutions enabled through advanced low power Bluetooth beacons and enterprise cloud management. TraceSafe's leading cloud management solution ensures both user privacy and comprehensive administrative control. TraceSafe's patented contact tracing bracelet has already been deployed in mission-critical quarantine applications around the world in partnership with leading governments. In addition to their government work, TraceSafe is developing leading-edge solutions for Enterprise, Healthcare, Education, Government and large-scale venue management.

About TELUS

TELUS (T, TU) is a dynamic, world-leading communications and information technology company with $15.3 billion in annual revenue and 15.7 million customer connections spanning wireless, data, IP, voice, television, entertainment, video and security. We leverage our global-leading technology to enable remarkable human outcomes. Our longstanding commitment to putting our customers first fuels every aspect of our business, making us a distinct leader in customer service excellence and loyalty. TELUS Health is Canada's largest healthcare IT provider, and TELUS International delivers the most innovative business process solutions to some of the world's most established brands.

Driven by our passionate social purpose to connect all Canadians for good, our deeply meaningful and enduring philosophy to give where we live has inspired our team members and retirees to contribute more than $700 million and 1.3 million days of service since 2000. This unprecedented generosity and unparalleled volunteerism have made TELUS the most giving company in the world.

For more information about TELUS, please visit telus.com, follow us @TELUSNews on Twitter and @Darren_Entwistle on Instagram.

About Hockey Canada

Hockey Canada is the governing body for hockey in Canada and a member of the International Ice Hockey Federation (IIHF), with a membership through its 13 member associations of over 750,000 players, coaches and officials. Hockey Canada is a not-for-profit organization that creates leading-edge hockey development programs for its members to deliver in communities across Canada; provides consistent rules and regulations and various other membership services from coast to coast to coast; manages numerous regional, national and international hockey championships and events; and leads the operation of all teams that represent Canada in international competition. Hockey Canada's mission is to lead, develop and promote positive hockey experiences. For more information on Hockey Canada, please visit HockeyCanada.ca or follow through social media on Facebook and Twitter.

Program details can be found on hockeycanada.ca/tracesafe or en français hockeycanada.ca/tracesafe_fr.

For more information and media enquiries, please contact:

TraceSafe
Trevor Beckman
tbeckman@storycommunications.ca
403-461-7733

Hockey Canada
Spencer Sharkey
ssharkey@hockeycanada.ca
905-906-5327

The Canadian Securities Exchange has in no way approved or disapproved the contents of this news release.

Statements in this news release may contain forward-looking statements that are based on TraceSafe's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to expectations regarding the TraceSafe assets and their application, future business plans and relationships, future developments in respect of COVID-19 and solutions adopted in response to the virus, and the deployment and acceptance of the TraceSafe technology. Although TraceSafe believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict, including the suitability of our products to help businesses and governments reopen, competition, the spread or containment of COVID-19 and government responses thereto and general economic and market conditions. Therefore, outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and TraceSafe undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE: TraceSafe Inc.

ReleaseID: 620743